OVID THERAPEUTICS INC (OVID) Fundamental Analysis & Valuation

NASDAQ:OVID • US6904691010

Current stock price

2.62 USD
+0.32 (+13.91%)
At close:
2.614 USD
-0.01 (-0.23%)
After Hours:

This OVID fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

1

1. OVID Profitability Analysis

1.1 Basic Checks

  • In the past year OVID has reported negative net income.
  • In the past year OVID has reported a negative cash flow from operations.
  • OVID had negative earnings in 4 of the past 5 years.
  • OVID had negative operating cash flow in 4 of the past 5 years.
OVID Yearly Net Income VS EBIT VS OCF VS FCFOVID Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M 100M

1.2 Ratios

  • The Return On Assets of OVID (-56.90%) is comparable to the rest of the industry.
  • OVID has a Return On Equity (-81.28%) which is in line with its industry peers.
Industry RankSector Rank
ROA -56.9%
ROE -81.28%
ROIC N/A
ROA(3y)-33.31%
ROA(5y)-29.01%
ROE(3y)-46.44%
ROE(5y)-51.69%
ROIC(3y)N/A
ROIC(5y)N/A
OVID Yearly ROA, ROE, ROICOVID Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50 -50 -100 -150

1.3 Margins

  • OVID does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
OVID Yearly Profit, Operating, Gross MarginsOVID Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -5K -10K -15K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

7

2. OVID Health Analysis

2.1 Basic Checks

  • OVID does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • OVID has more shares outstanding than it did 1 year ago.
  • Compared to 5 years ago, OVID has more shares outstanding
  • There is no outstanding debt for OVID. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
OVID Yearly Shares OutstandingOVID Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M
OVID Yearly Total Debt VS Total AssetsOVID Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M

2.2 Solvency

  • An Altman-Z score of 1.83 indicates that OVID is not a great score, but indicates only limited risk for bankruptcy at the moment.
  • With a decent Altman-Z score value of 1.83, OVID is doing good in the industry, outperforming 64.68% of the companies in the same industry.
  • There is no outstanding debt for OVID. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 1.83
ROIC/WACCN/A
WACC9.03%
OVID Yearly LT Debt VS Equity VS FCFOVID Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M 100M 150M

2.3 Liquidity

  • OVID has a Current Ratio of 4.24. This indicates that OVID is financially healthy and has no problem in meeting its short term obligations.
  • The Current ratio of OVID (4.24) is comparable to the rest of the industry.
  • A Quick Ratio of 4.24 indicates that OVID has no problem at all paying its short term obligations.
  • OVID has a Quick ratio of 4.24. This is comparable to the rest of the industry: OVID outperforms 51.63% of its industry peers.
Industry RankSector Rank
Current Ratio 4.24
Quick Ratio 4.24
OVID Yearly Current Assets VS Current LiabilitesOVID Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

4

3. OVID Growth Analysis

3.1 Past

  • The earnings per share for OVID have decreased by -6.38% in the last year.
  • Looking at the last year, OVID shows a very strong growth in Revenue. The Revenue has grown by 946.55%.
  • Measured over the past years, OVID shows a very negative growth in Revenue. The Revenue has been decreasing by -86.05% on average per year.
EPS 1Y (TTM)-6.38%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%15%
Revenue 1Y (TTM)946.55%
Revenue growth 3Y-86.05%
Revenue growth 5YN/A
Sales Q2Q%-23.7%

3.2 Future

  • Based on estimates for the next years, OVID will show a decrease in Earnings Per Share. The EPS will decrease by -3.38% on average per year.
  • Based on estimates for the next years, OVID will show a very strong growth in Revenue. The Revenue will grow by 63.21% on average per year.
EPS Next Y-30.82%
EPS Next 2Y-10.7%
EPS Next 3Y-12.9%
EPS Next 5Y-3.38%
Revenue Next Year892.86%
Revenue Next 2Y-49.61%
Revenue Next 3Y-47.73%
Revenue Next 5Y63.21%

3.3 Evolution

  • The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
OVID Yearly Revenue VS EstimatesOVID Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 100M 200M 300M 400M
OVID Yearly EPS VS EstimatesOVID Yearly EPS VS EstimatesYearly EPS VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 2 -2 -4

More info and screens

Find the best growth stocksShow best growing peers

0

4. OVID Valuation Analysis

4.1 Price/Earnings Ratio

  • OVID reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for OVID. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
OVID Price Earnings VS Forward Price EarningsOVID Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
OVID Per share dataOVID EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.2 -0.2 -0.4

4.3 Compensation for Growth

  • A cheap valuation may be justified as OVID's earnings are expected to decrease with -12.90% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-10.7%
EPS Next 3Y-12.9%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. OVID Dividend Analysis

5.1 Amount

  • OVID does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

OVID Fundamentals: All Metrics, Ratios and Statistics

OVID THERAPEUTICS INC

NASDAQ:OVID (3/20/2026, 8:15:51 PM)

After market: 2.614 -0.01 (-0.23%)

2.62

+0.32 (+13.91%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)03-16
Earnings (Next)05-11
Inst Owners47.56%
Inst Owner Change96.3%
Ins Owners3.07%
Ins Owner Change1.09%
Market Cap341.07M
Revenue(TTM)6.61M
Net Income(TTM)-36.33M
Analysts87.5
Price Target4.26 (62.6%)
Short Float %4.34%
Short Ratio3.13
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)26.21%
Min EPS beat(2)-11.2%
Max EPS beat(2)63.62%
EPS beat(4)2
Avg EPS beat(4)18.8%
Min EPS beat(4)-11.2%
Max EPS beat(4)63.62%
EPS beat(8)5
Avg EPS beat(8)-9.79%
EPS beat(12)8
Avg EPS beat(12)-3.55%
EPS beat(16)11
Avg EPS beat(16)1.7%
Revenue beat(2)1
Avg Revenue beat(2)3959.29%
Min Revenue beat(2)-1.54%
Max Revenue beat(2)7920.11%
Revenue beat(4)2
Avg Revenue beat(4)2003.21%
Min Revenue beat(4)-60.64%
Max Revenue beat(4)7920.11%
Revenue beat(8)6
Avg Revenue beat(8)1066.77%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-3.87%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0.51%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 51.6
P/FCF N/A
P/OCF N/A
P/B 7.63
P/tB 7.63
EV/EBITDA N/A
EPS(TTM)-0.5
EYN/A
EPS(NY)-0.47
Fwd EYN/A
FCF(TTM)-0.29
FCFYN/A
OCF(TTM)-0.29
OCFYN/A
SpS0.05
BVpS0.34
TBVpS0.34
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -56.9%
ROE -81.28%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-33.31%
ROA(5y)-29.01%
ROE(3y)-46.44%
ROE(5y)-51.69%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.1
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr -1%
Cap/Sales 0.06%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.24
Quick Ratio 4.24
Altman-Z 1.83
F-Score3
WACC9.03%
ROIC/WACCN/A
Cap/Depr(3y)104.96%
Cap/Depr(5y)109.64%
Cap/Sales(3y)52.29%
Cap/Sales(5y)32.03%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-6.38%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%15%
EPS Next Y-30.82%
EPS Next 2Y-10.7%
EPS Next 3Y-12.9%
EPS Next 5Y-3.38%
Revenue 1Y (TTM)946.55%
Revenue growth 3Y-86.05%
Revenue growth 5YN/A
Sales Q2Q%-23.7%
Revenue Next Year892.86%
Revenue Next 2Y-49.61%
Revenue Next 3Y-47.73%
Revenue Next 5Y63.21%
EBIT growth 1Y41.07%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year9.56%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y12%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y11.78%
OCF growth 3YN/A
OCF growth 5YN/A

OVID THERAPEUTICS INC / OVID Fundamental Analysis FAQ

Can you provide the ChartMill fundamental rating for OVID THERAPEUTICS INC?

ChartMill assigns a fundamental rating of 3 / 10 to OVID.


What is the valuation status of OVID THERAPEUTICS INC (OVID) stock?

ChartMill assigns a valuation rating of 0 / 10 to OVID THERAPEUTICS INC (OVID). This can be considered as Overvalued.


What is the profitability of OVID stock?

OVID THERAPEUTICS INC (OVID) has a profitability rating of 1 / 10.


What is the financial health of OVID THERAPEUTICS INC (OVID) stock?

The financial health rating of OVID THERAPEUTICS INC (OVID) is 6 / 10.


What is the earnings growth outlook for OVID THERAPEUTICS INC?

The Earnings per Share (EPS) of OVID THERAPEUTICS INC (OVID) is expected to decline by -30.82% in the next year.